YB new stock pitches (Fri, Apr 24)

Precipio, Inc. (PRPO), a specialty cancer diagnostics company focused on eradicating cancer misdiagnosis (which affects approximately one in four oncology biopsies), operates a dual-engine business model consisting of high-margin pathology services and a proprietary products division headlined by HemeScreen, a reagent-based screening technology utilizing proprietary PCR that delivers molecular results in under 24 hours at a fraction of traditional sequencing costs. The company reached a critical inflection point in Q3 2025, achieving its first positive adjusted EBITDA of $469,000 and positive operating cash flow of $285,000 on $6.8 million in revenue (up 30% year-over-year), demonstrating operating leverage as the pathology services division expanded gross margins to 46% with a path to 50% by mid-2026 through volume scaling in underutilized CLIA-certified laboratories. Management explicitly stated no intention to return to equity markets for funding, terminated the ATM facility, and in January 2026 fully repaid the $1.1 million Change Healthcare emergency advance using internal cash, while the capital structure has been cleaned through resolution of legacy financial warrants (only 10,000 vendor warrants at $60 strike remain). Early 2025 MolDx approval for NGS testing panels unlocked Medicare reimbursement for approximately 50% of hematopathology patients, effectively doubling addressable revenue per case in the services division, driving the pathology segment to approximately $2 million in monthly revenue. The company estimates FY2025 revenue of $24.5 million and projects FY2026 revenue of $30.6 million (25% growth), with a fully diluted share count of 2 million shares yielding a market cap of $50 million and enterprise value of $47.8 million (1.6x sales versus a 3x peer average). A re-rating to 3x revenue would imply an enterprise value of $92 million and share price of approximately $46 (roughly a double from current $25), while the IV-Cell cytogenetics product has seen minimal traction and international interest but does not generate significant revenue. Key risks include sales momentum hiccups that could disrupt the self-funding model on a lean cash balance, execution risk in the distributor-led HemeScreen rollout requiring effective third-party coordination, potential FDA scrutiny of Laboratory Developed Tests that could increase validation costs, and competitive pressure from larger national labs, though Precipio's sub-specialized Academic Connection model (leveraging experts from institutions like Yale School of Medicine) provides differentiation. The upcoming appearance at Planet Microcap conference in Las Vegas marks significant investor outreach as the company transitions from a 'broken' microcap phase with limited institutional coverage to an offensive growth strategy, with CEO Ilan expressing commitment to never returning to capital raises.

Read the full article here. Read time: 6 min

MiniMed Group (MMED), a recent MedTech IPO spun off from Medtronic (MDT) in early March 2024 at $20 per share and now trading in the mid-teens, has been added to the watchlist due to an unusual incentive structure. MDT retains approximately 90% ownership and plans to exit its full position in around six months, likely through an exchange offer, creating a thin float situation. Key executives including the CEO, CFO, and General Counsel received Performance Stock Units (PSUs) that vest only if MMED's stock price reaches $32.05 by the later of March 2027 or when MDT disposes of its stake, representing roughly 60% upside from the IPO price and over 100% from current levels. The company received FDA approval for its next-generation insulin pump shortly after the IPO, suggesting management and MDT see a fundamental path to achieving the $32.05 price target. The combination of aggressive stock price incentives tied to PSU vesting, a controlling shareholder planning near-term disposal, and a thin float creates potential for significant volatility and possible upside overshooting, making this a rare and potentially explosive setup worth monitoring.

Read the full article here. Read time: 2 min

Fittech Co., Ltd. (6706.TW), a Taiwan-based OEM with a market cap of approximately $300 million, is pivoting from LED/micro-LED manufacturing to CPO (co-packaged optics) after facing growth challenges from Chinese competition and waning demand. The company's patent TWM680691U, published on March 1, 2026, appears designed to automate fiber array unit (FAU) assembly that matches Foci's 2D zigzag structure patent (US 20260036750, published February 5, 2026), which nests a second layer of fibers in valleys created by fibers in v-grooves to increase density. Fittech's patented machinery features fibers separated by a layering component that feeds into a connector with a window for automated optical inspection (AOI) and UV-cured glue application, with the layering component withdrawn to allow fibers to nest into v-grooves before being stacked with corresponding Himax WLO blocks. Recent aggressive hiring activity over the last 2-3 weeks—including full-time shift work positions in a clean room environment for new processes and machines—signals a production ramp rather than R&D, coinciding with Foci's plans to spend aggressively on FAU automation in Q2. The investor has taken a position in both Fittech and Himax, noting this is a high-risk binary outcome where Fittech either wins the Foci contract for COUPE or faces a tough spot, making it a particularly risky high-risk/reward CPO automation play not suitable for all investors.

Read the full article here. Read time: 2 min